Welcome to the new fibrotech.com.au
Fibrotech is developing orally active anti-fibrotic inhibitors to treat an unmet clinical need. Fibrotech’s lead compound will be developed to treat the underlying pathological fibrosis that occurs in kidney and heart failure.
HR
Fibrotech drug pipeline
Fibrotech Therapeutics was formed in May 2006 to develop novel drug candidates for the treatment of the fibrosis prevalent in such chronic conditions as chronic kidney disease (CKD), chronic heart failure (CHF), pulmonary fibrosis (PF) and arthritis. Fibrotech has prepared over 120 analogues, many of which are novel chemical entities and are markedly improved antifibrotic agents.
